Efficacy of Symptoms of Lower Urinary Tract Dysfunction Research Network Symptom Index-29 Questionnaire in Assessing Alpha-blocker Treatment Response in Patients With Benign Prostatic Hyperplasia: A Prospective, Multicenter, Cohort Study

dc.authorid0000-0002-7684-3632
dc.authorid0000-0002-4647-4864
dc.authorid0000-0002-0176-5887
dc.authorid0000-0002-5822-7799
dc.authorid0000-0003-0202-0454
dc.authorid0000-0002-3386-971X
dc.contributor.authorArıkan, Özgür
dc.contributor.authorKazan, Ozgur
dc.contributor.authorArikan, Mehmet Gurkan
dc.contributor.authorUcar, Taha
dc.contributor.authorParpucu, Alihan
dc.contributor.authorIplikci, Ayberk
dc.contributor.authorÇakıcı, Mehmet Çağlar
dc.date.accessioned2025-05-10T19:43:51Z
dc.date.issued2025
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractOBJECTIVE To evaluate the efficacy of the symptoms of the Lower Urinary Tract Dysfunction Research Network Symptom Index-29 (LURN SI-29) questionnaire in assessing alpha-blocker treatment response in patients with lower urinary tract symptoms (LUTS). METHODS This prospective, non-randomized, multicentre trial included males with LUTS who visited urology outpatient clinics between January and April 2023. The most employed LUTS questionnaire is the International Prostate Symptom Score (IPSS), while the LURN SI-29 was also utilized. Prospective monitoring comprised the completion of IPSS and LURN SI-29 forms, uroflowmetry, and residual urine assessment prior to the initiation of alpha-blocker therapy and at the conclusion of the first month of treatment. RESULTS The study cohort comprised 135 patients. There was a significant enhancement in the mean IPSS, which decreased from 18.4 to 11.2 (P = .001). Furthermore, the mean LURN SI-29 score exhibited a significant decline, from 37.02 to 22.4 (P = .001). The improvement in IPSS and LURN SI-29 scores was 67.1% +/- 54.3% and 64.2% +/- 34.1%, respectively. Additionally, these improvements were found to be correlated (Pearson correlation coefficient = 0.79, R2 = 0.63, P = .001). The mean Qmax increased from 10.3 to 11.9 ml/s (P = .001). No significant difference was identified between alpha-blocker types. CONCLUSION A strong correlation was observed between LURN SI-29 and IPSS among patients with LUTS who were initiated on alpha-blocker therapy. LURN-SI-29 may be employed for the purpose of evaluating the efficacy of alpha-blocker therapy and may additionally offer insight into the domains of incontinence, post-micturition symptoms, and pain. UROLOGY 196: 249-253, 2025. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
dc.identifier.doi10.1016/j.urology.2024.11.023
dc.identifier.endpage253
dc.identifier.issn0090-4295
dc.identifier.issn1527-9995
dc.identifier.pmid39551396
dc.identifier.scopus2-s2.0-85210543507
dc.identifier.scopusqualityQ2
dc.identifier.startpage249
dc.identifier.urihttps://doi.org/10.1016/j.urology.2024.11.023
dc.identifier.urihttps://hdl.handle.net/20.500.14730/10754
dc.identifier.volume196
dc.identifier.wosWOS:001423964400001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofUrology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.subjectQuality-Of-Life
dc.subjectPrevalence
dc.subjectMen
dc.subjectPss
dc.titleEfficacy of Symptoms of Lower Urinary Tract Dysfunction Research Network Symptom Index-29 Questionnaire in Assessing Alpha-blocker Treatment Response in Patients With Benign Prostatic Hyperplasia: A Prospective, Multicenter, Cohort Study
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
10754.pdf
Boyut:
605.17 KB
Biçim:
Adobe Portable Document Format